Applied Filters
HLK adds medical devices expert to Bristol office
Haseltine Lake Kempner has added Jo Deas as a partner to its chemistry and life sciences team, effective January 20.
Breaking: EPO revokes Broad’s CRISPR patent
In a dramatic reversal, a European Patent Office’s board of appeal has upheld the revocation of a Broad Institute CRISPR/Cas9 patent.
Breaking: EPO board to refer key issues in Broad appeal to higher panel
The European Patent Office intends to refer questions in the Broad Institute’s ongoing CRISPR patent case to the enlarged board of appeal, meaning the case is set to drag out further.
EPO appeals board weighs-up Broad’s CRISPR claims
The first day of a landmark hearing on CRISPR ownership dealt nearly exclusively with untangling linguistic arguments, lawyers following the proceedings told LSIPR.
Jennewein takes on Nestlé over baby formula patents
German biotech Jennewein has accused Nestlé Nutrition of infringing patents covering a process of purifying human milk oligosaccharides to make its infant formula.
Bayer begins $240m AI drug discovery project with Exscientia
Germany-based Bayer is collaborating with Exscientia, an artificial intelligence (AI)-driven drug discovery company, to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.
Nestlé Skin Health has face injection infringement claims thrown out
Nestlé Skin Health will not face claims that it misappropriated trade secrets related to a training platform for teaching medical professionals how to perform facial injections, a US court has ruled.
Merck KGaA secures CRISPR patents in Japan and Singapore
The Japan Patent Office and the Intellectual Property Office of Singapore have each granted Merck KGaA a patent covering the use of paired CRISPR nickases.
LSPN Europe: understand our business models, say in-house lawyers
The best lawyers acting for life sciences companies make sure they fully understand their clients’ business models, said in-house counsel at Life Sciences Patent Network 2019.
Roche buys fibrotic diseases biotech in $1.4bn deal
Switzerland-based Roche has agreed to acquire Promedior and its portfolio of molecules for serious fibrotic diseases.
